Table 1 Patients characteristics
From: Can pegylated interferon improve the outcome of polycythemia vera patients?
peg-INF group | HU group | p value | |
|---|---|---|---|
Sex, n (%) | |||
Male | 19 (63) | 23 (66) | 0.841 |
Female | 11 (37) | 12 (34) | |
Age at diagnosis (years) | |||
Median (range) | 49 (18–64) | 53 (29–65) | 0.180 |
Age at treatment start | |||
Median (range) | 54 (32–65) | 55 (36–65) | 0.645 |
Time from diagnosis to study entry (months) | |||
Median (range) | 11 (0–179) | 18 (0–169) | 0.631 |
Palpable spleen | |||
N (%) | 16 (55) | 14 (42) | 0.316 |
Cardiovascular risk factors | |||
N (%) | 16 (53) | 20 (57) | 0.758 |
Previous thrombosis | |||
N (%) | 5 (17) | 9 (26) | 0.376 |